Stockscreener 앱 받기
7.97
3.51%
0.27
시간 외 거래:
7.97
전일 마감가:
$7.70
열려 있는:
$7.73
하루 거래량:
209.82K
Relative Volume:
1.09
시가총액:
$162.03M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-1.6101
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
+6.98%
1개월 성능:
+26.71%
6개월 성능:
+42.58%
1년 성능:
-40.74%
1일 변동 폭
$7.705
$8.228
1주일 범위
$7.2327
$8.228
52주 변동 폭
$4.09
$17.23
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
7.97 | 162.03M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com
ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World
Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus
Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals discovers new 17β-HSD13 inhibitors - BioWorld MedTech
Enanta Pharmaceuticals’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com Nigeria
Enanta to present RSV drug study results at ESPID 2025 By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - BioSpace
Enanta to present RSV drug study results at ESPID 2025 - Investing.com
(ENTA) On The My Stocks Page - news.stocktradersdaily.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Citizens JMP Increases Enanta (ENTA) Price Target to $23 | ENTA Stock News - GuruFocus
ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView
Enanta stock price target raised to $23 by JMP - Investing.com Canada
Enanta price target raised to $23 from $21 at Citizens JMP - TipRanks
Enanta (ENTA) Reports Revenue Miss and Advances Drug Development Programs | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - BioSpace
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals Reports Q2 Loss of $1.06 Per Share, Beati - GuruFocus
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - News-Times
(ENTA) Trading Report - news.stocktradersdaily.com
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - MSN
11 Best Breakout Stocks to Buy According to Analysts - Insider Monkey
JMP Securities maintains Enanta stock with $21 target - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
(ENTA) Investment Report - news.stocktradersdaily.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan
(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada
Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Enanta Pharmaceuticals Inc 주식 (ENTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
29,305 |
| Luu Brendan | Chief Business Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
36,047 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 06 '24 |
Sale |
8.06 |
866 |
6,980 |
17,918 |
| Or Yat Sun | Chief Scientific Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
369,109 |
| MELLETT PAUL J | Chief Fin. & Admin Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
91,710 |
| Luly Jay R. | President and CEO |
Dec 06 '24 |
Sale |
8.06 |
5,142 |
41,445 |
801,638 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 15 '24 |
Option Exercise |
8.99 |
5,375 |
48,321 |
27,092 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 15 '24 |
Sale |
17.08 |
5,375 |
91,805 |
21,717 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 11 '24 |
Sale |
15.07 |
4,299 |
64,786 |
23,988 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 12 '24 |
Sale |
15.04 |
2,271 |
34,156 |
21,717 |
1.45%
0.86%
자본화:
|
볼륨(24시간):